Waystar Weighs Sale Amid Software Sector Slump

Healthcare software firm Waystar is exploring strategic options, including a potential sale, according to sources familiar with the matter. The company, which is based in Lehi, Utah, and Louisville, Kentucky, has enlisted investment bank Evercore to assist with the process. Discussions are in preliminary stages, and a definitive decision has not been reached, insiders revealed under anonymity due to the confidentiality of the information.

Market Challenges and Strategic Repositioning

Waystar, known for its technology that aids hospitals and doctors in managing payments, was listed on the stock market two years ago. Despite its initial success, the company's market value has plummeted to approximately $4.8 billion, following a 24% decline in share prices this year. This downturn mirrors a broader selloff in the software sector, raising questions about investor confidence in the industry.

The firm initially positioned itself as a technology company focused on automating administrative tasks in healthcare, rather than relying on human resources. This approach was intended to attract higher valuations typical for tech companies. However, concerns about the impact of advancements in artificial intelligence on traditional software models have emerged, according to a July report by Morgan Stanley analysts.

Background and Ownership

Waystar was formed in 2017 through the merger of Zirmed and Navicure, two healthcare revenue management firms. Its ownership includes significant stakes held by private equity firm EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, who collectively took the company public in 2024. EQT remains the largest shareholder with a 13% stake, while CPPIB and BlackRock Institutional Trust Company hold 10% and 8% respectively, according to data from LSEG.

While EQT and BlackRock have declined to comment on the current situation, CPPIB has yet to respond to requests for comments. Evercore, the advisory bank for this possible transaction, also did not immediately reply to inquiries.

Potential Outcomes and Investor Sentiment

The exploration of a sale by Waystar could serve as a barometer for investor interest in software companies, particularly those operating in the healthcare sector. The company’s shares initially surged from $20 to a peak of $45 in 2025, as investors were drawn to its tech-focused narrative. However, shifts in market dynamics and technological advancements have since pressured its stock performance.

Whether Waystar will proceed with a sale or find alternative strategic paths remains uncertain. The decision will likely hinge on investor appetite and the broader market environment for healthcare technology solutions.